| scholarly article | Q13442814 |
| P50 | author | Grzegorz Grynkiewicz | Q9281814 |
| Neil S French | Q42703283 | ||
| P2093 | author name string | Esther van Duijn | |
| Wouter H J Vaes | |||
| Alessandro Schipani | |||
| Kevin B Park | |||
| Mark A Turner | |||
| Andrew M Selby | |||
| Caroline Earnshaw | |||
| Colin R Garner | |||
| Francis P Crawley | |||
| Heili Varendi | |||
| Jane Lass | |||
| Lindsay Byrne | |||
| Rianne deLigt | |||
| Sarah Siner | |||
| Wioletta Maruszak | |||
| P2860 | cites work | Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. | Q38024216 |
| Paediatric drug development: the impact of evolving regulations | Q38189937 | ||
| Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever | Q40281291 | ||
| The phase 0 microdosing concept | Q41942832 | ||
| A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. | Q42488776 | ||
| European Bioanalysis Forum Recommendation: Scientific Validation of Quantification by Accelerator Mass Spectrometry | Q42679469 | ||
| Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin | Q43244925 | ||
| A generic biokinetic model for Carbon-14. | Q44463582 | ||
| Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. | Q46401554 | ||
| Automated combustion accelerator mass spectrometry for the analysis of biomedical samples in the low attomole range | Q47215601 | ||
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 | ||
| Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science | Q50707361 | ||
| Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials | Q51796989 | ||
| The problems in scaling adult drug doses to children | Q51919764 | ||
| Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. | Q54599494 | ||
| Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry | Q57150351 | ||
| A preliminary evaluation of accelerator mass spectrometry in the biomedical field | Q74555091 | ||
| A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models | Q79757014 | ||
| Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry | Q81097075 | ||
| Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults | Q87010638 | ||
| Microdosing: A Critical Assessment of Human Data | Q30559553 | ||
| Development and validation of a dried blood spot-LC-APCI-MS assay for estimation of canrenone in paediatric samples | Q33445178 | ||
| Practical Experience of Using Human Microdosing with AMS Analysis to Obtain Early Human Drug Metabolism and PK Data | Q33748891 | ||
| Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability | Q34105874 | ||
| Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough? | Q34239948 | ||
| Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement | Q34314738 | ||
| Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept | Q34422598 | ||
| The use of isotopes in the determination of absolute bioavailability of drugs in humans | Q34550493 | ||
| Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. | Q34596303 | ||
| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs | Q35075780 | ||
| Microdosing and drug development: past, present and future | Q35940544 | ||
| Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations | Q36627208 | ||
| Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls | Q36748125 | ||
| Improving pediatric dosing through pediatric initiatives: what we have learned | Q37098241 | ||
| The ontogeny of drug metabolism enzymes and implications for adverse drug events | Q37136222 | ||
| A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects | Q37173944 | ||
| Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children | Q37279407 | ||
| Facilitating pharmacokinetic studies in children: a new use of dried blood spots | Q37760638 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 157-167 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis | |
| P478 | volume | 80 |
| Q91584992 | Dose-linearity of the pharmacokinetics of an intravenous [14 C]midazolam microdose in children |
| Q37701128 | Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development. |
| Q28817904 | Opportunities in low-level radiocarbon microtracing: applications and new technology |
| Q53211331 | Pediatric microdose and microtracer studies using 14C in Europe |
| Q99234124 | Phase 0/microdosing approaches: time for mainstream application in drug development? |
| Q38937832 | Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide. |
| Q94584518 | Proof of concept: first pediatric [14 C]microtracer study to create metabolite profiles of midazolam |
| Q47428031 | Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates |
| Q41456437 | Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism |
| Q50654753 | The expanding utility of microdosing |
| Q28818313 | Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology |
Search more.